Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 14, Issue 1, Pages 1-11
Publisher
Springer Nature
Online
2011-10-19
DOI
10.1007/s11912-011-0202-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Will Evidence Ever Be Sufficient to Resolve the Challenge of Cost Containment?
- (2011) Arthur L. Caplan JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
- (2011) Miguel Martin et al. LANCET ONCOLOGY
- Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients
- (2010) M. Ronzoni et al. ANNALS OF ONCOLOGY
- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
- (2010) I. E. Smith et al. ANNALS OF ONCOLOGY
- Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials
- (2010) A. Valachis et al. BREAST CANCER RESEARCH AND TREATMENT
- Circulating biomarkers of bevacizumab activity in patients with breast cancer
- (2010) Neelima Denduluri et al. CANCER BIOLOGY & THERAPY
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Molecular and Clinical Aspects of Targeting the VEGF Pathway in Tumors
- (2010) Grzegorz Korpanty et al. Journal of Oncology
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
- (2009) E. D. Saad et al. ANNALS OF ONCOLOGY
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
- (2009) Konstantin J. Dedes et al. EUROPEAN JOURNAL OF CANCER
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
- (2009) Robert Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- RiBBON 1 and RiBBON 2: Phase III Trials of Bevacizumab with Standard Chemotherapy for Metastatic Breast Cancer
- (2008) Joyce A. O'Shaughnessy et al. Clinical Breast Cancer
- Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer
- (2008) S. X. Yang et al. CLINICAL CANCER RESEARCH
- Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study
- (2008) A. Dowlati et al. CLINICAL CANCER RESEARCH
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started